# A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

> **NCT03866499** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beta Pharma Shanghai** · enrollment: 369 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** BPI-7711
- **DRUG:** Gefitinib
- **DRUG:** Placebo Tablet
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT03866499
- **Lead sponsor:** Beta Pharma Shanghai
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2023-11-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866499, "A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03866499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*